The DOI matches its Crossref record.
End-stage renal disease in India and Pakistan: Burden of disease and management issues
Open accessAbstract
In the absence of national registries, no reliable data are available on the incidence and prevalence of end-stage renal disease (ESRD) in India and Pakistan. The incidence of ESRD is likely to be higher than that reported from the developed world, with chronic glomerulonephritis being the most common cause, accounting for more than one third of patients, while diabetic nephropathy accounts for about one fourth of all patients in India. Patients are generally younger (mean age 42 years) at the time of detection of ESRD and two-thirds first see a nephrologist after they have reached end stage. Treatment of ESRD is a low priority for the cash-strapped public hospitals and in the absence of health insurance plans, less than 10% of all patients receive any kind of renal replacement therapy. The vast majority of patients starting hemodialysis die or stop treatment because of cost constraints within the first three months, and less than 2% patients are started on ambulatory peritoneal dialysis. Although renal transplantation is the cheapest option, only about 5% of all patients with ESRD end up having a transplant. Living related donor transplants constitute 30 to 40% of all transplants in India, but there is a conspicuous gender bias with female donors donating kidneys for their male relatives. Cadaveric transplantation has yet to pick up and accounts for less than 2% of all transplants. The enactment of legislation to regulate renal transplantation in India has not been able to prevent unrelated (paid) donor transplants, which constitute 60 to 70% of all renal transplants. Cyclosporine, azathioprine and prednisolone continue to be the backbone of post-transplant immunosuppression, with cyclosporine being stopped in a significant proportion at one year post-transplant to cut down costs. Increasing awareness of renal disease amongst the population and general practitioners could result in early diagnosis of chronic renal failure and give opportunity for preventive strategies to delay the onset of ESRD. Preemptive transplantation and use of generic cyclosporine can help bring down the costs of treatment. Innovative and affordable health insurance policies can also increase the number of patients who receive effective treatment for ESRD in these two countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications
Schieppati, A., & Remuzzi, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09801.x · Cited by 447
Singh, A. K., Farag, Y. M., Mittal, B. V., Subramanian, K. K., Reddy, S. R. K., Acharya, V. N., Almeida, A. F., Channakeshavamurthy, A., Ballal, H. S., P, G., et al. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-114 · Cited by 420
The incidence of end-stage renal disease in India: A population-based study
Modi, G. K., & Jha, V. (2006) · Kidney International · doi:10.1038/sj.ki.5001958 · Cited by 348
How can we achieve global equity in provision of renal replacement therapy?
White, S. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.07.041715 · Cited by 291
Metadata
- Authors
- Sakhuja, V., & Sud, K.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 63
- Issue
- 83
- Pages
- S115-S118
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2131449451
- Cited by
- 209
- References
- 0
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: End-stage renal disease in India and Pakistan: Burden of disease and management issues. https://app.cochat.ai/papers/10.1046/j.1523-1755.63.s83.24.x
- The paper
- Sakhuja, V., & Sud, K. (2003). End-stage renal disease in India and Pakistan: Burden of disease and management issues. Kidney International. https://doi.org/10.1046/j.1523-1755.63.s83.24.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.